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ABSTRACT
Pemphigus is a bullous autoimmune disease
that affects the skin and mucous membranes. It
is very difficult to establish the etiology and the
triggering factors that influence reactivations in
pemphigus vulgaris (PV). The case of a 33-year-
old male with chronic history of intranasal
cocaine consumption is presented in this
report. We present the clinical case of the
patient, followed for a total of 86 weeks, with
ten relapses secondary to probable cocaine use.
The patient was admitted to the emergency
department after presenting polymorphic der-
matosis characterized by blisters, vesicles, and
excoriations extending from the oral cavity to
the thorax, and to the inguinal and genital
regions, affecting approximately 35 % of the
body surface area with a score of 56 on the
Pemphigus Skin Disorder Index. Skin biopsies
were compatible with PV diagnosis. The patient
had clinical improvement with a combination
of methylprednisolone 500 mg intravenously
(IV) and cyclophosphamide 500 mg IV every
15 days, along with prednisone 50 mg orally
(PO) q24 h and mycophenolic acid 500 mg PO
q6 h. Persistent cocaine use is highly likely to be
the factor triggering lesion reactivation and
responsible for the torpid evolution. We cannot
definitively conclude whether the change from
azathioprine to mycophenolic acid after the
tenth relapse was the adjuvant medication
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responsible for the end of the consolidation
phase and complete remission on therapy. This
case study could potentially serve as a guide for
management of patients who continuously
persist with cocaine use, leading to a clinical
picture refractory to multiple therapeutic
schemes.
Keywords: Acantholytic lesion; Cocaine;
Corticosteroid therapy; Mycophenolic acid;
Pemphigus vulgaris; Relapse
INTRODUCTION
Pemphigus is a rare blistering disease that
affects the skin and mucous membranes. It is an
autoimmune disease characterized by produc-
tion of pathogenic autoantibodies directed
against desmosome proteins of keratinocytes in
the epidermis [1]. There are two basic forms of
pemphigus, viz. pemphigus vulgaris (PV) and
pemphigus foliaceus (PF). The etiological factors
associated with pemphigus are blunt trauma,
ionizing radiation, stress, cocaine use, herpes
simplex virus, Epstein–Barr virus, cytomegalo-
virus, and medication (e.g., hormones, vacci-
nes, nonsteroidal antiinflammatory drugs)
[2–5].
In PV, blisters develop above the stratum
basale and are associated with autoantibodies
against desmoglein (Dsg)3 (i.e., a cell surface
adhesion molecule of keratinocytes). Mean-
while, in PF, blisters form under the stratum
corneum and are associated with autoantibod-
ies against Dsg1 [2]. PV diagnosis requires the
following: (1) clinically compatible presenta-
tion, (2) lesions histopathologically compatible
with direct immunofluorescence microscopy of
perilesional skin, and (3) serological detection
of autoantibodies against the surface of epithe-
lial cells by indirect immunofluorescence
microscopy and/or enzyme-linked immunosor-
bent assay (ELISA) [6]. Among the differential
diagnoses for PV are PF, pemphigus erythe-
matosus, pemphigus vegetans, and paraneo-
plastic pemphigus. Other dermatologic lesions
with similar morphology include herpes sim-
plex, bullous pemphigoid, dermatitis
herpetiformis, erythema multiforme, and
lichen planus [7]. We present the clinical case of
a patient with ten relapses, probably secondary
to cocaine use. The patient’s evolution was
torpid and refractory to first-line treatment,
despite reported adequate adherence to treat-
ment and without presenting other triggering
factors. This is the first case reported in litera-
ture in which a patient with multiple relapses
secondary to continuous cocaine use is refrac-
tory to multiple therapeutic schemes, but ulti-
mately has complete remission after suspension
of cocaine use and establishment of an effective
therapeutic scheme. Approval from the ethical
committee was not required due to the nature
of this case report. Abiding by the 1964 Decla-
ration of Helsinki and its later amendments or
comparable ethical standards, patient anonym-
ity was guaranteed. Upon hospital admission,
the patient signed an informed consent form
permitting use of their clinical file information
for didactic and research purposes.
CLINICAL PRESENTATION
A 33-year-old male arrived at the emergency
department, presenting polymorphic-type der-
matosis with 1 week of evolution, characterized
by blisters, vesicles, and excoriations on the
scalp and oral cavity that spread to the thorax
(anterior thorax impetiginized and posterior
thorax denuded; Fig. 1), extending to the ingu-
inal and genital area (sparing the penis and
glans). Among the patient’s personal history, he
reported long-lasting alcohol abuse and drug
addiction, consisting of daily inhalation of
approximately 200 mg cocaine during the pre-
vious 2 years. Cocaine use was suspended hours
prior to hospital admission. The patient’s family
history included a father and two second-degree
relatives with arterial hypertension under
treatment. The patient had no history of skin,
hematologic, autoimmune, or degenerative
diseases or neoplasms.
The integumentary system suffered from
dermal lesions (vide supra) affecting 35 % of the
total body surface (BSA) with a score of 56 on
the Pemphigus Skin Disorder Index (PDAI).
Thoracic, abdominal, and genital lesions were
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positive for the Nikolsky sign at the edges, while
the lower extremities presented blisters in
healing phase. Clarithromycin, acyclovir, and
nonsteroidal antiinflammatory drugs (NSAIDs)
were indicated during the first week, without
presenting clinical improvement. Upon admis-
sion, the patient had the following vital signs:
blood pressure 110/80 mmHg, heart rate
90 bpm, respiratory rate 20 rpm, temperature
37.5 C, weight 65 kg, height 167 cm, body
mass index 23.1 kg/m2.
During hospitalization, the patient had
intermittent fever without time predominance.
Laboratory results at admission are presented in
Supplementary Table 1. Due to personal history
of drug use, the following tests were requested:
hepatitis B virus, hepatitis C virus, human
immunodeficiency virus, and urinalysis for
benzodiazepines, barbiturates, cannabis,
cocaine, methamphetamines, and opiates; all
results except urinalysis for cocaine metabolites
were reported as negative. In search of an
autoimmune etiology, the following tests were
requested: anti-double-stranded deoxyribonu-
cleic acid (\ 0.5 U/mL) and antinuclear anti-
body (6.58 U/mL); both reported as negative
(Supplementary Table 2). Twenty-four hours
after admission, skin biopsy was performed on
the anterior thorax, with a suprabasal bullous
lesion and acantholysis, compatible with PV
(Fig. 2). Treatment was initiated with methyl-
prednisolone intravenously (IV), azathioprine
and prednisone orally (Table 1). Refer to the
supplemental material for a detailed description
of the case presentation and evolution.
CLINICAL EVOLUTION
The patient had torpid clinical evolution with
multiple relapses (Fig. 3). The management
strategy for this patient can be divided into six
phases (Table 1). The first phase was performed
when the patient was hospitalized. The second
phase lasted only 1 month, while the third
phase 5 months, the fourth phase 5 months,
and the fifth phase 6 months; the final phase
(i.e., until the time of manuscript preparation)
included maintenance therapy until the patient
achieved complete remission off therapy. In the
absence of rituximab and intravenous
immunoglobulin (IVIg) in our hospital, con-
sidering the therapeutic effectiveness of the
schemes used, slight modifications of previous
therapeutic algorithms were made and imple-
mented. Full-body computerized tomography
(CT) scan was performed to rule out paraneo-
plastic pemphigus, reporting negative result for
neoplasia (Fig. 4).
Cocaine consumption was corroborated after
each relapse despite alleged suspension via uri-
nalyses for cocaine and its metabolites (Sup-
plementary Table 2). The patient was first given
information about the possible complications
of chronic and acute cocaine use, then referred
to the social work department for provision of
information about support groups and non-
profit organizations dedicated to addiction
management. Finally, 6 months after the
change from azathioprine to mycophenolic
acid, the patient achieved complete PV
Fig. 1 a Photograph of posterior thorax. Active lesions (i.e., blisters, vesicles, and excoriations) with denuded regions of the
back. b Photograph of face and anterior thorax. Impetiginized anterior thorax, scalp, and oral cavity, spreading to the thorax
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remission (Fig. 5) and was followed on a
monthly basis with management therapy with
only prednisone 25 mg per os (PO) q24 h. The
patient was free of any PV relapses at the time of
preparation of this manuscript, after 3 months
with the maintenance therapeutic scheme of
prednisone 25 mg PO q24 h.
DISCUSSION
To the best of the authors’ knowledge, this is
the first report in literature of a case in which a
patient with multiple relapses secondary to
continuous cocaine use is refractory to multiple
therapeutic schemes, but ultimately achieves
complete remission after suspending cocaine
use and establishing an effective therapeutic
scheme. The patient presented in this case was
followed for a total of 86 weeks, having a total
of ten relapses. The patient had relapses despite
good therapeutic adherence; nonetheless, the
patient continued cocaine consumption with-
out reducing the frequency or amount con-
sumed for over 14 months after initiation of
therapeutic management. The therapeutic
management was determined by two factors:
first medication availability (or lack of access to
rituximab and IVIg in our hospital), and sec-
ondly the risk–benefit balance associated with
use of glucocorticoids and the clinical
evolution.
The optimal therapeutic strategy for PV and
PF is not known. Treatment of pemphigus is
through use of glucocorticoids, reducing mor-
tality from 75 % to less than 10 % [8]. Multiple
treatment modalities and regimens are avail-
able, making the choice of treatment complex
[9]. The management of this patient can be
divided into six phases. During the first phase,
the patient was administered three IV boluses of
methylprednisolone (i.e., 3 g) due to the sever-
ity of the clinical picture and to control the
dermatosis immediately. Use of high glucocor-
ticoid doses has been reported previously, with
administration of methylprednisolone IV (i.e.,
10–20 mg/kg or 250–1000 mg/day) or equiva-
lent doses of dexamethasone for up to five
consecutive days [10]. The theoretical basis of
use of glucocorticoid boluses is to achieve faster
and more efficient control of the disease com-
pared with conventional oral glucocorticoid
Fig. 2 a Histopathology of skin biopsy, 509, hematoxylin
and eosin staining. Presence of suprabasal bullous lesion.
b Histopathology of skin biopsy, 1009, hematoxylin and
eosin staining. Presence of acantholytic cells within a
bullous lesion with detachment of the rest of the epidermis
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administration; furthermore, bolus administra-
tion allows a reduction in long-term mainte-
nance corticosteroid doses and their inherent
side-effects due to chronic use. However, these
benefits remain theoretical, as bolus therapy has
not been demonstrated to have any added value
over conventional therapy [10]. Due to the
chronicity of PV, adverse effects are frequently
associated with use of these corticosteroids. Use
of adjuvant therapy (e.g., rituximab, azathio-
prine, cyclophosphamide, and mycophenolate)
increases the efficacy of glucocorticoids while
decreasing the effective dose [6, 8].
PV is a chronic, relapsing–remitting autoim-
mune disorder. Full disease remission is difficult
to achieve in PV, having variable clinical out-
comes, often determined by the individual’s
characteristics and environment. According to
Murrell and colleagues [6, Table 4], the follow-
ing considerations are important for PV moni-
toring : (1) control of disease activity, (2) end of
consolidation phase, (3) complete remission on







with active lesions (%)
Pemphigus Skin
Disorder Index
Event Treatment Frequency of
IV treatment
1 0 35 56 Admission M0, P0, A0 Once
2 2 24 19 Discharge M, P, A Monthly
3 4 15 21 1st relapse M, C, P, A Monthly
3 5 9 12 2nd discharge M, C, P, A Monthly
3 6 15 12 2nd relapse M, C, P, A Monthly
3 9 12 11 3rd relapse M, C, P, A Monthly
3 11 15 19 4th relapse M, C, P, A Monthly
3 15 12 17 5th relapse M, C, P, A Monthly
3 20 15 16 6th relapse M, C, P, A Monthly
3 24 12 14 7th relapse M, C, P, A Monthly
3 26 12 12 8th relapse M, C, P, A Monthly
4 31 10 7 9th relapse M, C, P, A Bimonthly
4 48 15 16 10th relapse and
change of
treatment
M, C, P, A Bimonthly











6 86 0 3 Last evaluation P1 Daily
IV intravenous,M0 methylprednisolone boluses of 1 g IV q24 h for three doses, P0 prednisone 75 mg (per os, PO) q24 h, A0
azathioprine 50 mg PO q24 h,M methylprednisolone 500 mg IV, C cyclophosphamide 500 mg IV, P prednisone 50 mg PO
q24 h, A azathioprine 150 mg PO q24 h, MA mycophenolic acid 500 mg PO q6 h, P1 prednisone 25 mg PO q24 h
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therapy, (4) complete remission off therapy, (5)
relapse/flare, and (6) minimal therapy. We
decided to use the PDAI to track the clinical
evolution and response to the therapeutic
management of the patient. The PDAI was
found to better assess true clinical severity and
was more reproducible than the Autoimmune
Bullous Skin Disorder Intensity Score (ABSIS)
[11]. In patients with moderate to severe PV, the









































Clinical evolution through severity index
Fig. 3 Graphical representation of clinical evolution. Total body surface with active lesions. X-axis, time in weeks. Y-axis,
percentage of body surface with active lesions
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severity changes [11]. The second phase of
therapeutic management, in which standard
therapy was provided with methylprednisolone
500 mg IV, prednisone 50 mg PO, and azathio-
prine 150 mg PO, served as an adjustment
phase. Since the patient experienced his first
Fig. 4 Thoracoabdominal computerized tomography (CT) scan without contrast. No evidence of signiﬁcant alterations
Fig. 5 a Photograph of anterior thorax and abdomen. Posttreatment residual lesions in thoracic and abdominal regions.
b Photograph of right thigh. Scabs covering lesions, with residual spots
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relapse during this second phase, the third
phase was implemented after a month. The
third phase included methylprednisolone
500 mg IV and cyclophosphamide 500 mg IV
once a month, along with maintaining the oral
doses of prednisone and azathioprine. Due to
the pattern of relapse occurrence, the fourth
therapeutic management scheme was imple-
mented. The fourth phase was characterized by
maintaining the same doses of oral prednisone
and azathioprine, but the frequency of the IV
medications (i.e., methylprednisolone 500 mg
IV and cyclophosphamide 500 mg IV) was cut
in half to bimonthly. The patient did not
experience remission, although his cocaine
consumption was maintained for almost
4 months. The fifth phase was initiated after the
tenth and final relapse. In this phase, azathio-
prine was replaced by mycophenolic acid
500 mg q6 h PO. This decision was based on the
study of Enk and Knop [12], in which 12
patients with PV had relapses and were man-
aged with azathioprine (1.5–2 mg/kg) and
prednisolone (2 mg/kg), but 11 patients
improved clinically when azathioprine was
replaced by mycophenolic acid (i.e., 2 g/day).
After 6 months relapse free on therapy with
mycophenolic acid PO, prednisone PO,
methylprednisolone IV, and cyclophosphamide
IV bimonthly, the sixth phase was initiated.
After clinical improvement, a risk–benefit
assessment was carried out, and it was decided
that the patient could be progressed to a
maintenance therapy until complete remission
off therapy could be initiated. The maintenance
therapy established was prednisone 25 mg PO
q24 h, and to date of manuscript preparation
(i.e., 3 months), the patient was relapse free.
An additional objective of PV management is
to limit use of drugs with side-effects (e.g., glu-
cocorticoids, mycophenolic acid) until the
conclusion of therapeutic management or a
minimum effective dose is reached [2, 6].
Treatment time for pemphigus is variable, with
duration ranging from 1.5 to 20 years [13]. The
first-line treatment in pemphigus is use of sys-
temic corticosteroids such as prednisone at
dosage of 0.5 to 1.5 mg/kg/day. Systemic corti-
costeroids (e.g., oral or intravenous pulses) can
be combined with immunosuppressive
adjuvant treatment from the beginning of
management; furthermore, this clinical deci-
sion should be considered in cases with
increased risk of complications due to pro-
longed use of steroids (i.e. [ 4 months) or the
need for continuous use of dosages above
10 mg/day [6]. However, there is limited evi-
dence that addition of adjuvant immunosup-




One of the limitations of this case report is the
completeness of the patient’s diagnosis. The
patient was diagnosed based on the clinical
picture and skin biopsy (i.e., presence of supra-
basal bullous lesions with acantholysis). Tissue
immunofluorescence microscopy or serological
detection of autoantibodies against desmosome
proteins was not possible due to lack of avail-
ability of laboratory reagents. Durdu and col-
leagues [14] reported presence of acantholytic
cells in 100 % of cytological samples from
patients with pemphigus, with specificity of
43 % for PV in a sample of 400 patients. Pres-
ence of IgG autoantibodies that bind to the
surface of keratinocytes or desmoglein is the
gold standard for pemphigus diagnosis and
serves for its differentiation from other vesicu-
lobullous or pustular diseases [15, 16].
Another limitation of this study is the level
of certainty regarding adherence to therapy by
the patient. Although the patient reported good
adherence to the oral medication and did not
miss any of his scheduled IV treatments, he did
continue his cocaine consumption. Since our
hospital does not have laboratory capabilities to
perform high-performance liquid chromatogra-
phy, concentration levels of prednisone, pred-
nisolone, azathioprine, cyclophosphamide, and
mycophenolic acid in plasma, whole blood,
urine or bound-to-plasma proteins were not
quantified. Furthermore, cocaine metabolite
serum levels were not available to monitor the
patient’s relapses (due to the resource-con-
strained environment in which our dermatol-
ogy clinic operates). In an attempt to associate
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the disease activity and cocaine consumption, a
surrogate proxy for metabolite serum levels was
used in this case report (i.e., cocaine metabolite
urinalyses). Although urinalysis for cocaine
metabolite detection was performed after each
visit, as reported in Supplementary Table 2,
serum levels of cocaine metabolites would be
ideal to provide further insight into the disease
activity (e.g., to correlate disease activity with
serum levels of cocaine metabolites). Although
cocaine metabolites have a blood clearance
half-life of 3.6 h and up to 3 days in urine, both
are adequate for clinical detection of cocaine
use (i.e., serum sensitivity of 90% and specificity
of 98.4% and urine sensitivity of 100% and
specificity of 90.6%) [17].
The etiologies considered and investigated
included immunizations, hormonal therapy,
and other medications. The medications that
have been associated with pemphigus include
penicillamine, captopril, enalapril, cilazapril,
fosinopril, ramipril, nonsteroidal antiinflam-
matory drugs, rifampicin, levodopa, cephalos-
porins, phenobarbital, interferon, propranolol,
and nifedipine [2]. Drug addictions such as
cocaine consumption have also been associated
with PV [3, 4]. PV associated with cocaine use is
not frequent. In the case presented herein, the
patient suffered ten relapses. Ngo and col-
leagues [4] reported a case of PV associated with
cocaine use, where clinical improvement was
achieved after 18 months of treatment with
prednisone 80 mg PO q24 h and mycopheno-
late mofetil 1.5 g PO q24 h. Skin lesions associ-
ated with cocaine use exhibit a broad clinical
spectrum. The most frequent forms and clinical
characteristics of dermatological manifestations
secondary to cocaine consumption are leuko-
cytoclastic vasculitis and thrombotic vascu-
lopathy [18]; however, in this patient, both
histopathological findings were ruled out.
CONCLUSIONS
It is very difficult to establish the etiology and
the triggering factors that influence reactiva-
tions in PV. In this case, persistence of cocaine
use (as corroborated by the patient and multiple
urinalyses) is likely to be the factor triggering
lesion reactivation and responsible for the tor-
pid evolution characterized by ten relapses
within 1 year. Although the patient’s clinical
evolution might have been similar if the patient
had ceased cocaine consumption earlier, the
event (i.e., cocaine consumption cessation or
change in therapy) having a greater effect on
the clinical improvement cannot be distin-
guished. Furthermore, the authors do not claim
direct causation between cocaine cessation and
pemphigus remission, but associate the clinical
improvement with both cocaine cessation and
the change to mycophenolic acid in the thera-
peutic management. The patient showed clini-
cal improvement with a combination of
methylprednisolone 500 mg IV and cyclophos-
phamide 500 mg IV every 15 days, along with
prednisone 50 mg PO q24 h and mycophenolic
acid 500 mg PO q6 h. The patient continued
without relapses even after establishing main-
tenance therapy (i.e., prednisone 25 mg PO
q24 h). We cannot definitively conclude whe-
ther the change from azathioprine to
mycophenolic acid after the tenth relapse was
the adjuvant medication responsible for the end
of the consolidation phase and complete
remission on therapy. To date of manuscript
preparation, the patient had not achieved
complete remission off therapy. This case study
could potentially serve as a guide for manage-
ment of patients who continuously persist with
cocaine use, leading to a clinical picture refrac-
tory to multiple therapeutic schemes. We
definitively encourage discontinuation of the
triggering factor, yet cocaine abuse is a complex
disease and must be approached through a
multidisciplinary group to address both the
medical and psychosocial factors.
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